Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

14.90
-0.0950-0.63%
Post-market: 15.100.2000+1.34%19:59 EST
Volume:1.26M
Turnover:18.79M
Market Cap:1.06B
PE:-4.48
High:15.34
Open:15.08
Low:14.84
Close:15.00
52wk High:62.75
52wk Low:5.95
Shares:71.37M
Float Shares:40.42M
Volume Ratio:0.61
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3285
EPS(LYR):-1.8918
ROE:-54.33%
ROA:-30.72%
PB:3.68
PE(LYR):-7.88

Loading ...

Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

Reuters
·
Dec 03

MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud

Reuters
·
Dec 02

MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

Reuters
·
Nov 25

MoonLake Immunotherap Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 21

MoonLake price target lowered to $26 from $30 at H.C. Wainwright

TIPRANKS
·
Nov 21

MoonLake Immunotherapeutics Faces Investor Class Action Over Alleged Securities Fraud

Reuters
·
Nov 19

Moonlake Immunotherapeutics Faces Class Action Lawsuit Over Alleged Securities Fraud

Reuters
·
Nov 12

MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud

Reuters
·
Nov 07

MoonLake Immunotherapeutics Reports Q3 2025 Financial Results

TIPRANKS
·
Nov 07

RBC Capital Sticks to Its Hold Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Nov 07

Stock Track | MoonLake Immunotherapeutics Plummets 5.10% Amid Investor Class Action Lawsuit

Stock Track
·
Nov 07

Wedbush Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Nov 06

MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments Drive Buy Rating

TIPRANKS
·
Nov 06

MoonLake Immunotherapeutics: Promising Clinical Trials and Strategic Regulatory Advances Boost Confidence in Sonelokimab

TIPRANKS
·
Nov 06

BRIEF-MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Reuters
·
Nov 05

MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate

Benzinga
·
Nov 05

MoonLake Immunotherapeutics - Prices 7.1 Mln Class a Ordinary Shares at $10.50 Each

THOMSON REUTERS
·
Nov 05

BRIEF-MoonLake Immunotherapeutics Q3 EPS USD -1.1

Reuters
·
Nov 05

MoonLake Immunotherapeutics reports third quarter 2025 results and announces new clinical trial data

Reuters
·
Nov 05

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data From Clinical Trials of Its Nanobody® Sonelokimab

THOMSON REUTERS
·
Nov 05